Compare Mesoblast Limited (MESO) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VanEck Semiconductor ETF — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while VanEck Semiconductor ETF trades at $587.57. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SMH | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $668.91 |
52-Week Low | $12.88 | $286.43 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
SMH trades at $588.23, up 3.31% today, with a neutral technical signal and mixed momentum indicators. The ETF faces headwinds from semiconductor sector volatility and recent downgrades, while institutional interest remains active with new stakes from firms like Ferguson Shapiro LLC. Support and resistance levels suggest consolidation near current prices, with key levels at $560 support and $587 resistance.
Outlook is cautious due to sector rotation and AI-driven volatility, though long-term demand for semiconductors remains strong. Risks include tariff impacts and competitive ETF performance, but strategic positioning in AI and memory markets offers growth potential for patient investors amid near-term uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
